DETAILED ACTION
Notice of Pre-AIA or AIA Status
1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Information Disclosure Statement
2. The information disclosure statement (IDS) submitted on September 17, 2026 was in compliance with the provisions of 37 CFR 1.97 and 37 CFR 1.98. The IDS was considered. A signed copy of form 1449 is enclosed herewith.
Response to Amendment
3. The amendments to the claims filed on September 17, 2026 have been fully considered. The amendments are sufficient to overcome the 35 USC 102 rejection over WO 2017009806 which is withdrawn.
4. The amendments are not sufficient to overcome the outstanding Improper Markush rejection or objection of claim 17. Below are responses to Applicant’s remarks.
Claim 17 was previously objected to for depending on a base rejected claim. This objection is maintained because the independent claim remains rejected.
The claims were previously rejected on the basis that they contain improper Markush grouping of alternatives. The Markush grouping was improper because the alternative defined do not share a single structural similarity and common use due to the variable ring structures in the core afforded by A, B and C. Applicants have amended the claims to recite A is benzo. However, rings B and C are still generically defined to contain variable core structures due to these variables Applicants state that a substantial core structure exists due to benzothiazole This argument is not found to be persuasive as the benzothiazole is only part of the core which is further defined by variables B and C.
For the reasons stated, the Improper Markush rejection is maintained. Claims 1, 2, 7-9, 12, 14-16 and 18 remain rejected.
Conclusion
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE YOO whose telephone number is (571)272-9074. The examiner can normally be reached Mon-Fri 8-5.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SUN JAE YOO/Primary Examiner, Art Unit 1621